Siemens Healthineers has reported a net income of €616m, or €0.55 per diluted share, for the fourth quarter ended 30 September 2024, a 15% rise compared to €537m, or €0.48 per diluted share, for the same quarter in 2023.
The medical device maker’s net income for the fourth quarter (Q4) of fiscal year 2024 (FY2024) increased by 31% compared to €469m for the third quarter of FY 2024 (Q3 2024).
The company reported net revenue of €6.32bn for Q4 2024, a 5% increase compared to €6.05bn for the same quarter in 2023, and a 17% rise compared to €5.42bn for Q3 2024.
Siemens Healthineers reported earnings before interest and taxes (EBIT) of €944m for Q4 2024, a 10% increase compared to €858m for the respective quarter in 2023.
The German healthcare technology company reported an income before tax of €844 for Q4 2024, a 9% rise compared to €775m for the same quarter in the previous year.
Siemens Healthineers CEO Bernd Montag said: “We achieved our targets for the fiscal year with a very good fourth quarter despite the current market weakness in China.
“This underlines the fundamental strength of our company and the contribution of the entire Healthineers team. We will carry this momentum into the 2025 financial year.”
Siemens Healthineers reported a net income of €1.94bn, or €1.73 per diluted share, for the full fiscal year 2024 (FY 2024), a 29% rise compared to €1.50bn, or €1.34 per diluted share, for the fiscal year 2023 (FY 2023).
The German company reported a net revenue of €22.36bn for FY 2024, a 3% increase compared to €21.68bn for FY 2023.
Siemens Healthineers reported earnings before interest and taxes (EBIT) of €2.8bn for FY2024, a 31% rise compared to €2.13bn for FY 2023.
The medical device maker reported an income before tax of €2.52bn for FY 2024, a 31% increase compared to €1.92bn for FY 2023.
Last month, Siemens Healthineers launched the Atellica Integrated Automation on Atellica CI analyser to consolidate 25 tasks that are usually handled manually by laboratory staff.
